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Abstract
Prebiotics are ingredients selectively fermented by the intestinal microbiota that promote changes 
in the microbial community structure and/or their metabolism, conferring health benefits to the 
host. Studies show that β (1–4) galacto-oligosaccharides [β (1–4) GOS], lactulose and fructo-
oligosaccharides increase intestinal concentration of lactate and short chain fatty acids, and stool 
frequency and weight, and they decrease fecal concentration of secondary bile acids, fecal pH, and 
nitroreductase and β-glucuronidase activities suggesting a clear role in colorectal cancer (CRC) 
prevention. This review summarizes research on prebiotics bioassimilation, specifically β (1–4) 
GOS, and their potential role in CRC. We also evaluate research that show that the impact of 
prebiotics on host physiology can be direct or through modulation of the gut intestinal 
microbiome, specifically the probiome (autochtonous beneficial bacteria), we present studies on a 
potential role in CRC progression to finally describe the current state of β (1–4) GOS generation 
for industrial production.
1. Introduction
1.1. Prebiotics: Definition and scope of review
Prebiotics are “nondigestible food ingredients that beneficially affect the host by selectively 
stimulating the growth and/or activity of one or a limited number of bacteria in the colon, 
and thus improves host health”[41]. The gut bacteria play an active role in the digestion of 
carbohydrates, a fermentative process that yields short chain fatty acids (SFCA) like acetic, 
propionic and butyric acids, and various gases like hydrogen, methane and CO2. The 
concept of prebiotics is relatively recent; however, the differences between non-digestible 
and digestible carbohydrates, and the methods to quantify them were established early in the 
last century. Digestible carbohydrates were considered those available for digestion and 
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absorption in the small intestine that rapidly increased blood glucose levels[83] (had a high 
glycemic index) whereas non-digestible carbohydrates were not digested and hence had a 
low glycemic index. The methods for determination of digestible carbohydrates target the 
reducing sugars, including sucrose and starch as a measure of the available carbohydrates in 
food products. The non-digestible carbohydrates are reported as the amount of insoluble 
residue, corrected for protein and ash (reviewed by McCleary[84]).
Prebiotics are short chain oligosaccharides resistant to digestion in the upper gastrointestinal 
tract; thus, they can reach the colon undigested, to selectively stimulate the growth of the 
beneficial members of the intestinal the microbiota or probiome[6] that carry functional β-
galactosidases and/or β-glucosidases. The most recent definition of prebiotics states that “a 
dietary prebiotic is an ingredient selectively fermented that results in specific changes in the 
composition and/or activity of the gastrointestinal (GI) microbiota thus conferring benefit(s) 
upon host health”[42]. Three commercially available dietary ingredients: galacto-
oligosaccharides (GOS), lactulose, and fructo-oligosaccharides (FOS) have been used as 
food additives in Japan and Europe. In the United States, the Food and Drug Administration 
(FDA) has not stated health claims for probiotics or prebiotics but requires a notification of 
safety when applying for commercialization of a new dietary ingredient. Additionally, the 
FDA Centers for Biologic Evaluation and Research and Drug Evaluation and Research 
(CBER and CDER, respectively) published a draft document regarding the need to file an 
Investigational New Drug application when doing human research[1] in which is mentioned 
that, according to the National Center for Complementary and Alternative Medicine 
(NCCAM), prebiotics are included in the domain called “biologically based practices”, 
which “includes, but is not limited to, probiotics, botanicals, animal-derived extracts, 
vitamins, minerals, fatty acids, amino acids, proteins, whole diets, and functional foods”. 
Prebiotics commercialized in the US that have submitted notification to be considered as 
new dietary ingredients (NDI), and have GRAS (generally regarded as safe status) status for 
use in foods and term infant formulas, include Vivinal GOS® (Friesland Foods Domo®) 
and Oligomate 55N/55NP (Yakult Pharm. Ind. Co.). Vivinal GOS® is generated using the β-
galactosidase from Bacillus circulans while Oligomate, which has been used as a food 
ingredient in Japan for several years, is generated using whole cells of Sporobolomyces 
singularis overexpressing its own β-hexosyl transferase. Figure 1 shows the proportion of 
components in commercial and a non-commercial, enriched GOS formulation recently 
developed[28]. The commercial β (1–4) galacto-oligosaccharides [β (1–4) GOS] formulations 
contain approximately 50% β-(1–4) GOS, and residual glucose, lactose and galactose, 
carbohydrates that may enhance growth of non-probiomic bacteria. The host and the 
microbial physiological responses to prebiotics, which are poorly digested by endogenous 
enzymes and fermented by the intestinal microbiota containing functional β-galactosidases 
and/or β-glucosidases are referred as “prebiotic effects” and have been extensively 
documented in humans and animals[55, 75, 94].
1.1.1. Galacto-oligosaccharides (GOS)—GOS are the most inexpensive alternative 
often added to infant formulas to mimic the beneficial effects of the oligosaccharides present 
in human breast milk and is one of the most extensively evaluated prebiotic. They are 
considered prebiotics as was originally defined by Gibson and Roberfroid[41]: they are not 
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absorbed in the upper part of the gastrointestinal tract, they are specific substrates for one or 
a group of beneficial bacteria of the probiome (resulting in the modulation of the intestinal 
microbiota in favor of a healthier composition), and have beneficial systemic effects on the 
host. Technically, GOS can have α- or β-configurations by the nature of the glycosidic 
bonds between the sugar molecules (Table 1). The majority of published scientific articles 
use the term GOS when referring to β (1–4) GOS, while the abbreviation TOS has been 
alternatively employed[31]. β (1–4) GOS are generally produced by enzymatic 
transglycosylation using β-galactosidases or β-glucosidases and have a generic formula of β 
(1–4) [DGalactose]n-D-Glucose where n ranges between 3 and 10 sugar moieties[104]. Due 
to their glycosidic bond, they are not metabolized in the small intestine reaching the colon 
intact, where they serve as substrate for specific members of the microbiota capable of 
hydrolyzing the galactose-glucose bonds[106]. These carbohydrates and the carbohydrate 
fragments formed from the hydrolysis of the complex polymeric substances are further 
transformed by the butyrate-producers in the colon (see below a more detailed description of 
the effect of GOS on the intestinal microbiota). Products of GOS metabolism include 
SCFAs, lactate, acetate, and gases in proportions depending upon the α- or β-configuration 
of the sugars[31]. Bifidobacterium species are the most studied members of the probiome 
able to metabolize GOS, FOS, and human milk oligosaccharides (HMOs). Consequently, an 
increased abundance of bifidobacteria is the most reported effect of GOS and this is termed 
“bifidogenic effect” [29, 130].
1.1.1.1. GOS and CRC prevention: There is a strong genetic component in the 
development of colorectal adenomas or cancers, which in conjunction with environmental 
factors including diet and lifestyle have a major impact on risk (reviewed in [7]). Lifestyle 
aspects related to increased risk of CRC include elevated body mass index (BMI), obesity, 
and low physical activity[61, 80]. With regards to diet, elevated risk of CRC has been 
associated with high consumption of red and processed meat, refined grains, sweets, and 
alcohol, and a low consumption of fruits and vegetables[5, 115]. In this review, we examined 
the scientific literature and identified a number of factors, consisting of genetic and 
environmental parameters conducive to CRC, which can potentially be modulated by 
prebiotics to prevent gathering of the perfect storm. We have not included all 
chemopreventive agents of CRC like aspirin and other NSAIDs, multivitamins, hormones, 
and others[24], instead we assessed the literature specifically to identify research studies that 
suggest a role of GOS in CRC risk and prevention (Figure 2). The following sections list 
specific parameters with a role in CRC that could be modulated by prebiotics.
1.1.1.1.1. Bile acids: decreased concentration of secondary bile acids and increased 
concentration of primary bile acids?: In the intact intestinal tract, bacterial 
biotransformations of conjugated bile acids include deconjugation of bile acids (CBAs) to 
liberate free primary bile acids (cholic acid [CA] and chenodeoxycholic acid [CDCA]), 
oxidation of hydroxy groups at C-3, C-7 and C-12 with formation of oxo bile acids, and 
reduction of these oxo groups to either alpha- or beta-configuration[57]. Bacterial bile salt 
hydrolases (BSH, EC 3.5.1.24) are responsible for deconjugation of CBAs. The enzyme 
hydrolyzes the amide bond and liberate the glycine/taurine moiety from the steroid[11]. 
Quantitatively, the most important bacterial biotransformation is the 7 α-dehydroxylation of 
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CA and CDCA, to yield the secondary bile acids deoxycholic (DCA) and lithocholic (LCA) 
acids. A pioneer study by Reddy and collaborators[118] showed that the secondary bile acids 
sodium cholate or sodium chenodeoxycholate increased N-methyl-N′-nitro-N-
nitrosoguanidine (MNNG)-induced adenocarcinomas and adenomas in germ-free rats, and 
mainly adenomas in conventional female F344 rats. A study by the same group reported that 
patients with colon cancer excreted high levels of fecal secondary bile acids and cholesterol 
metabolites compared to healthy individuals[117]. Likewise, studies have reported that 
patients with colorectal adenomas had also increased fecal DCA and LCA[119] and serum 
DCA[10]. A more recent meta-analysis of 20 studies including a total of 1,226 individuals, 
aimed to review observational studies that examined the relationship between fecal bile 
acids and CRC or adenoma, reported that patients with adenomas and CRC had a higher 
concentration of total bile acids in stools. According to this analysis, patients with CRC (but 
not adenoma patients) had significantly increased concentrations of CDCA. One study 
reported markedly higher concentrations of fecal DCA in CRC patients[119], while most of 
the other studies included in the meta-analysis reported either no differences between CRC 
and control patients or higher concentrations of DCA in controls[151]. DCA excretion in 
patients with adenoma was significantly higher than controls. Conversely, LCA excretion 
was significantly higher in CRC patients, but not in adenoma patients[151]. An early study on 
high-risk CRC patients (individuals that had had adenomas removed) showed no significant 
differences in concentration of total bile acids in stools compared to controls[96]. No human 
studies have investigated the concentration or excretion of bile acids in patients with CRC or 
adenomas fed GOS. However, healthy men that consumed 15 g/day of either GOS, FOS or 
inulin excreted lower concentrations of fecal LCA and DCA, although values only reached 
statistical significance in the FOS and inulin groups for DCA[158].
1.1.1.1.2. Decreased fecal pH: Short chain fatty acids (SCFAs) are responsible for the 
neutralization of bases and the acidification of colon contents (reviewed by Newmark and 
Lupton[100]). Most SCFAs are generated by colon microbial fermentation of undigested 
dietary carbohydrates. A study investigating the effects of dietary cellulose and GOS on the 
development of dimethylhydrazine-induced CRC in rats fed low, medium, or high-fat diets 
showed that the pH in the cecum of animals fed high-GOS diets was 5.8, significantly lower 
than animals fed cellulose-diets, which had a pH ranging from 6.4 to 6.6[163]. According to 
data reviewed by Newmark and Lupton[100], the pH within the colon luminal environment 
can affect the composition and metabolic activity of the microbiota, the absorption of 
luminal components like SCFAs and minerals, the metabolism of drugs and carcinogens, 
enzymatic reactions such as those catalyzing secondary bile acid formation, and mucosal 
cell proliferation.
1.1.1.1.3. Increased SCFAs: Perhaps the most studied effect of prebiotics consumption is 
the increase of the major end-products of carbohydrate fermentation, SCFAs in the colon, of 
which butyrate has been extensively studied for its role in CRC prevention and 
progression[51, 71, 134], and that have been reported in studies in vitro[140], in animal 
models[62, 73, 109], and in human infants[35]. A fairly constant ratio of acetate > propionate > 
butyrate (in a molar ratio of approximately (60:20:20) has been reported in population 
surveys and measured in the intestinal contents of victims of sudden death, which however 
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can be altered by dietary changes[26, 165]. The role of SCFAs in the intestine include 
nutrition of the host colonic epithelium, modulation of the colonic pH, intracellular pH and 
cell volume, and regulation of proliferation and gene expression[8, 36, 90, 100]. Consequences 
of increased concentration of colonic SCFAs include decreased pH, which influences 
composition of the microbiota, decreased solubility of bile acids, increased absorption of 
minerals, and reduced absorption of ammonia (reviewed in [165]), all of which have a 
general correlation with SCFAs’ anticarcinogenic properties, particularly attributed to 
butyrate. A study conducted in 1,2-dimethylhydrazine (DMH)-treated rats fed either wheat 
bran, guar gum, or oat bran showed significantly fewer tumors in the rats fed wheat bran 
compared with those fed guar or oat bran, with the lowest tumor mass observed in rats fed 
wheat bran. These results suggested that fiber associated with high butyrate concentrations 
in the distal large bowel might be protective against CRC, while soluble fibers that do not 
raise distal butyrate concentrations may not be protective. It also suggested a relationship 
between butyrate production in vivo and suppression of tumor formation[86].
1.1.1.1.4. Increased lactate: Prebiotic consumption leads to a transient increase in lactate 
and butyrate in the colon and has been deemed of importance for CRC prevention[40]. 
However, utilization of GOS by butyrate generating (butyrogenic) bacteria has not been 
reported. The proposed mechanism by which prebiotics increase butyrate concentration is by 
cross-feeding (or syntropy) between different members of the colon microbiota[31]. In fact, 
GOS has been shown to increase microbial abundance of bifidobacteria and lactobacilli in 
the colon[29, 77], which can produce acetate, lactate, formate, ethanol, and succinate[39, 157], 
but have not been stated to produce butyrate. Therefore, the butyrogenic effect of prebiotics 
requires colonic accumulation of butyrate, which in turn needs a syntrophy (cross-feeding) 
mutualistic relationship between microbial production of lactate and its biotransformation to 
butyrate[12, 33, 132]. In fact, GOS consumption increased lactic acid concentration in fecal 
samples of healthy young men from an average of 266 mg/100 g to 379 mg/100 g of dry 
feces, although differences did not reach statistical significance[158].
1.1.1.1.5. Increased stool frequency and weight: Large bowel transit time or frequency of 
bowel movements is one of the most important factors affecting the structure and function of 
the colonic microbiota[78]. Moreover, low frequency of bowel movements (i.e. increased 
stool retention times) and reduced fecal weight have been associated with higher CRC risk. 
The best-documented influence of slow colonic transit is on bile acid metabolism by 
increasing DCA and raising cholesterol saturation of bile[72]. Bulking of the stool 
accelerates its transit, reducing the exposure time to irritants and carcinogens[27]. In an 
animal study, effects of dietary cellulose and GOS on the development of DMH-induced 
CRC were assessed in rats fed low-, medium- or high-fat diets[163]. In animals fed the high-
GOS diet, the cecal content was significantly increased in weight and significantly decreased 
in pH.
1.1.1.1.6. Decreased azoreductase, nitroreductase, and β-glucuronidase activities: 
Nitroreductases and azoreductases reduce nitro- and azo- components to aromatic amines 
through highly reactive reactions that generate mutagens and carcinogens while β-
glucuronidases hydrolyze glucuronic acid conjugates of heterocyclic amines also yielding 
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reactive metabolites that can cause damage to colonic mucosal cells[44]. In 1976, Goldin and 
Gorbach reported that the effect of diet on nitroreductase, azoreductase, and β-glucuronidase 
activities in male rats shifted from a diet with high vegetable and grain content to a diet 
consisting predominantly of beef[44]. The animals fed predominantly beef had significantly 
higher levels of these activities, which have been implicated in the conversion of 
procarcinogens into carcinogens[43, 124]. Moreover, over expression of nitroreductases has 
been reported in a Clostridium paraputrificum strain isolated from patients with colon 
cancer compared to clostridia from healthy individuals[99]. A research study showed that β-
glucuronidase and nitroreductase activities were reduced in rats fed GOS, while β-
glucosidase activity was increased[126], and the same trend was observed in humans[158]. 
More research on an actual correlation between these activities and CRC is clearly needed.
1.1.1.2. GOS and CRC progression: Although two animal studies have suggested that 
GOS was protective against the development of colorectal tumors, as demonstrated by an 
inhibitory effect on tumor incidence, multiplicity and size, regardless of the fat content of 
the diet [163, 164], studies on GOS and a potential role in CRC progression are lacking. One 
study reported that angiogenesis, the formation of new blood vessels from the preexisting 
vasculature and an obligatory event for the growth and progression of solid tumors beyond 
the size limit imposed by simple diffusion for nutrients, was inhibited by sulfated GOS. The 
study revealed that sulfated GOS with a low degree of polymerization (even 
pentasaccharides) were potent angiogenesis inhibitors with an influence on fibroblast growth 
factor FGF-2[65]. Of potential interest are the studies aimed to determine if human milk 
oligo-saccharides (HMOs), which are structurally similar to GOS, had a role in modulation 
of the neonatal intestinal development and enterocyte function. One study reported that 
exposure of the intestinal cell lines HT-29, HIEC, and Caco-2 to HMOs significantly 
inhibited cell proliferation[67]. Specifically, neutral oligosaccharides had an anti-
proliferative effect, a significant induction of apoptosis, and a minor increase in 
differentiation, and acidic oligosaccharides showed inhibition of the intestinal cell 
proliferation via induction of alkaline phosphatase activity. Moreover, HMOs induced 
growth arrest of intestinal cells by modulation of epidermal growth factor receptor (EGFR) 
signal pathways and cell cycle-associated gene expression[66].
1.1.2. Other prebiotics
1.1.2.1. Lactulose: Lactulose (4-0-β-d-galactopyranosyl-d-fructofuranose) is an artificial 
disaccharide composed of fructose and galactose, bonded together by a β (1–4)-glycosidic 
bond. The production and physiological effects of this disaccharide have been reviewed by 
Schuster-Wolff-Buhring et al.[135] and Panesar et al.[110]. Originally generated by intensive 
heating of lactose, several studies have demonstrated that lactulose induces growth of 
Bifidobacterium both in vitro[30, 108] and in vivo[14, 98, 159] but reports on the same effect on 
strains of Lactobacillus are mixed, with studies reporting either stimulation of 
Lactobacillus[127] or no significant differences in their growth rates[14, 50]. Besides the 
prebiotic, or more specifically, bifidogenic effect, lactulose has been shown to enhance 
colonic motility which correlates with its traditionally use as laxative in the treatment of 
constipation[139, 147, 150]. Additionally, a lower pH in the colon due to selective fermentation 
of this compound has been linked to an enhanced intestinal solubility of minerals which 
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resulted in its improved absorption[138, 156]. Similarly ascribed to the lowering of the 
intestinal pH[129] and generation of butyrate, one early study showed that lactulose 
decreased the pH of rat stools. Thus, rats with low pH stool had significantly fewer colon 
tumors after injections of 1,2-dimethylhydrazine (DMH) than rats treated with DMH 
alone[129]. Other studies have shown that lactulose decreased the incidence of aberrant crypt 
foci (ACF) and aberrant crypts generated in azoxymethane (AOM)-treated rats[23] and that 
lactulose at a dietary level of 0.3% significantly decreased the degree of DNA damage 
induced in cells of the colonic mucosa by DMH in rats harboring human gut microbiota[125].
High concentrations of secondary bile acids in feces, blood, and bile have been linked to 
cholesterol gallstone disease and colon cancer[85]. Consumption of lactulose (12 weeks, 60 
g/day) in patients with adenomas led to decreased colonic absorption of secondary bile 
acids, especially DCA. Other outcomes included decreased intestinal transit and fecal pH 
and increased stool frequency and weight[155]. A study by Roncucci et al.[121] reported that 
lactulose (20 g/day) taken daily was effective in reducing the recurrence rate of colon 
adenomas. Conversely, lactulose consumption did not affect the rectal mucosal proliferation 
in individuals with a family history of CRC[122].
1.1.2.2. Fructo-oligosaccharides (FOS): FOS are short to medium length chains of β-D 
fructans in which fructosyl units are bound by a β (2-1) osidic linkage[120]. β (2-1) fructans 
include inulin and FOS, and occur naturally in onion, chicory, garlic, asparagus, banana, 
artichoke, and other vegetables[75]. A study in 6 healthy volunteers given FOS for 11 days 
demonstrated that 89% of the ingested FOS was not metabolized in the small intestine, and 
none was excreted in stools, indicating that the portion reaching the colon was completely 
fermented by the colonic microbiota[92]. Unlike lactulose, FOS can be fermented by both 
Bifidobacterium and Lactobacillus strains[64, 87, 123] and studies have shown that FOS 
consumption results in increased numbers of Bifidobacterium[17] and Lactobacillus[131, 148] 
species. Interestingly, a relatively long term study in rats fed a basal low-fiber diet or the 
same diet containing 9 g/100 g of FOS for 2, 8 or 27 weeks showed that the increased 
concentrations of Lactobacillus and lactic acid in the cecum were abolished at 8 weeks; 
however, cecal SCFA concentration and molar butyrate ratio were higher in rats fed FOS at 
all-time points[69]. The prebiotic effect of FOS is dose dependent[17], also associated with a 
decrease of fecal pH in some animal models[13, 22] (results are inconclusive in 
humans[15, 16]), and increased production of lactic acid and SCFAs[34, 123].
Two animal models: the male Sprague-Dawley rat and ApcMin/+ mouse, which are 
heterozygous for a non-sense mutation of the Apc gene, the murine homologue of APC[95], 
are most commonly used to study the impact of dietary interventions on CRC. Studies in rats 
showed that FOS reduced the number of aberrant crypt foci in the colon of DMH-treated 
male Sprague-Dawley rats fed a 60 g FOS/kg diet for 35 days[56], and inhibited ACF 
formation and crypt multiplicity in AOM-treated male F344 rats (although at a lesser level 
than inulin)[116]. This end result was also demonstrated in rats but only when FOS was fed 
in combination with celecoxib (a non-steroidal anti-inflammatory drug)[20] or soybeans[46]. 
The alternative animal model currently used for preclinical testing of chemopreventive 
agents is the ApcMin/+ mouse model, although one major drawback of this mouse model is 
the occurrence of tumors predominantly in the small intestine and not the colon. Corpet and 
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Pierre[25] pointed out that most of the studied chemopreventive agents have a similar 
efficacy on large and small intestinal tumors, with specific exceptions that include NSAIDs 
(more protective in small intestine). Conversely, resveratrol, folic acid, uroguanlylin, 
selenium in broccoli, and FOS have a more prominent protective effect on the colon 
(reviewed in [25]). The FOS results are explained by the fact that FOS is not metabolized in 
the small intestine but fermented by the microbiota in the colon. Pierre et al.[112] reported 
that short-chain (sc) FOS decreased the number of colon tumors in ApcMin/+ mouse. 
Moreover, the histopathological examination of large tumors in the colon suggested a delay 
in the transition from adenomas to carcinomas in animals fed scFOS compared to controls, 
with adenomas being as numerous as adenocarcinomas in this group, whereas 
adenocarcinomas predominated in the other diets. The same group reported that scFOS also 
stimulates the local immune system with up-regulation of IL-15 by scFOS in the colon of 
Apc +/Min mice[9].
FOS impact on CRC studies in humans are scarce and contradictory at best. A study with 
healthy human volunteers revealed that FOS ingestion (12.5 g/day) led to an increase in 
fecal bifidobacterial counts and β-fructosidase activity but had no significant effect on fecal 
total anaerobes, pH, activities of nitroreductase, azoreductase, and β-glucuronidase, and 
concentrations of bile acids and neutral sterols (metabolic indexes potentially involved in 
colonic carcinogenesis)[15]. In a different study, 94 subjects with small adenomas (<10 mm 
in diameter), larger adenomas, or no adenomas were fed 5 g of scFOS twice daily for 3 
months. The study showed that long-term consumption of the prebiotic significantly 
increased fecal butyrate levels in patients with colon adenomas to the baseline level of 
adenoma-free patients. Additionally, scFOS consumption reduced fecal concentration of 
LCA, a secondary bile acid, in subjects without adenomas[18].
The above discussed research indicates that impact of prebiotics on the gut microbiome and 
parameters of CRC prevention is not exclusive of GOS. However, research shows that 
differences exist between the different prebiotics, lactulose with a more pronounced laxative 
effect and a lesser impact on the gut Lactobacillus population.
1.2. Modulation of the intestinal microbiota by GOS: Who can metabolize GOS in the 
intestinal tract? How is GOS metabolized by bacteria?
The vast majority of the intestinal bacteria have predominantly saccharolytic metabolisms; 
as a consequence, the availability of carbohydrates is almost certainly the most important 
factor controlling the composition and metabolic activities of the gut microbiota, despite the 
presence of large numbers of amino acid fermenting bacteria and syntrophic species in the 
colon. The bifidogenic effect of GOS has been documented in infants consuming formula 
containing polydextrose and β (1–4) GOS, which showed increased abundance of total 
Bifidobacterium species as well as specifically B. longum and B. infantis[133], and in infants 
consuming formula supplemented with β (1–4) GOS and FOS (in a 9:1 ratio)[52, 128], which 
showed not only increased abundance of bifidobacteria in stools of infants that consumed 
the prebiotics, but also increased abundance of lactobacilli and decreased numbers of 
Clostridium difficile.
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It cannot be assured that GOS will be fermented only by probiomic bacteria in the intestinal 
tract or that the products of fermentation will not benefit growth or activity of potential 
pathogens. However, the study by Davis et al.[29] done in 18 healthy adult human 
volunteers, whom were administered β (1–4) GOS during 16 weeks showed that only a few 
taxa other than bifidobacteria, were impacted by GOS. Statistically significant decreases 
were observed for the family Bacteroidaceae and the genus Bacteroides while abundance of 
Coprococcus comes and Faecalibacterium prausnitzii was significantly increased at doses 
of 5 and 10 g/day. Conversely, a recent study using an in vitro model of the colon, the 
TIM-2 system[91], and 13C-labeled GOS showed an increased abundance of several 
Bifidobacterium species being the most affected B. bifidum and B. catenulatum. β (1–4) 
GOS increased also abundance of Lactobacillus species (specifically L. gasseri and L. 
salivarius), and commensal, potentially pathogenic bacteria, including members of the 
family Enterobacteriaceae and Klebsiella species. In contrast, species of Bacteroides and 
Prevotella decreased in numbers, as well as Faecalibacterium prausnitzii (indicated with its 
former name, Fusobacterium prausnitzii in the publication), and species of Eubacterium, 
Ruminococcus and Lactococcus[77]. The study, which used the pooled fresh stools of 8 
healthy Dutch adult volunteers to create a standardized microbiota to use as inoculum for the 
study, also showed that production of SCFA was higher in the GOS pool, with higher 
acetate and lower propionate production, and slightly lower levels of butyrate. Additionally, 
levels of i-butyrate, i-valerate and ammonia (originated from protein fermentation) were 
lower in the GOS pool[77].
Metabolism of prebiotics in the colon is influenced by the respective sugar monomers, the 
degree of polymerization, and the type of glycosidic bonds[146]. It is accepted that GOS can 
resist hydrolysis by salivary and intestinal digestive enzymes but they are sensitive to 
hydrolysis by bacterial enzymes in the colon[113]. Although technically GOS could be 
hydrolyzed by the human intestinal β-galactosidase, hydrolysis is normally limited due to 
very weak enzymatic activities[76, 97]. Different enzymatic systems are involved in the 
hydrolysis of β-GOS, generally metabolized by β-galactosidases (β-Gal, EC 3.2.1.23), 
commonly known as lactases[21], since β-Gal enzymes are also responsible for the 
hydrolysis of terminal non-reducing β-D-galactose residue of the disaccharide lactose (4-O-
β-galactopyranosyl-D-glucopyranose). Bacterial β-Gal enzymes are quite ubiquitous. They 
are present in Proteobacteria, Firmicutes, Actinobacteria, the CFB (Bacteroidetes-Chlorobi-
Fibrobacteres) group, Verrucomicrobia, Spirochaetes, Victivallaceae, Thermotogales, 
Chloroflexi, Acidobacteriales, and over 350 species more. β-Gal enzymes are of 
biotechnological relevance due to their uses to synthetize GOS. In this section of the review, 
we will discuss how bacteria use β-Gal enzymes for GOS hydrolysis. In E. coli, β-Gal 
enzymes have two catalytic activities. They and hydrolyze lactose to galactose plus glucose, 
or convert lactose to another disaccharide, allolactose, which in turn induces the lac 
operon[82]. Due to the fact that the same structural β (1–4) bonds exist in lactose and GOS, 
the same enzyme is responsible for their hydrolysis. Lactose and GOS are evolutively 
related and represent the highest proportion of carbohydrates in the breast milk of mammals 
being the first and most natural source of nutrients for the newborn. Consequently, the most 
extensively characterized β-Gal enzymes are those from Bifidobacterium species. B. bifidum 
and some strains of B. longum subsp. longum exhibit a dedicated pathway for degrading 
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type I HMOs, that involves liberation of lacto-N-biose type I (LNB) and galacto-N-biose 
type I (GNB) from their natural substrates by extracellular enzymes (endo-α-N-
acetylogalactosaminidase[38] and/or lacto-N-biosidase[162]), transport and subsequent 
cleavage by the lacto-N-biose phosphorylase LnpA. The products of this process are α-
galactosylphosphate, which enters glycolysis, and N-acetylhexosamines, which enter the 
aminosugar metabolic cycle[105]. Strains of B. longum subsp. infantis characterized so far 
have shown no presence of lacto-N-biosidase homologs[74]. A recent study by Yoshida et 
al.[166] showed that B. longum subsp. infantis can directly incorporate lacto-N-tetraose 
(LNT) and hydrolyze it via a specific β-Gal enzyme. The authors identified two different β-
Gal enzymes (Bga42A and Bga2A) responsible for the degradation of type-1 and type-2 
HMOs respectively.
β-Galactosidases have been isolated and characterized from a number of Lactobacillus 
species, including L. pentosus[79], L. sakei[59], L. delbrueckii subsp. bulgaricus[103], L. 
plantarum[60], L. reuteri[102] and L. acidophilus[101]. However, the dedicated pathways and 
enzymes involved in GOS degradation have not been extensively characterized. A 
transcriptional analysis of genes induced in GOS-supplemented medium showed that in L. 
acidophilus, GOS specifically induced a cluster of genes encoding intracellular proteins 
involved with galactose and lactose metabolism, notably the LacS permease implicated in 
GOS transport[3]. β (1–4) GOS are structurally similar to oligosaccharides present in 
mammals breast milk and can be synthetically produced from lactose by the 
transglycosylating activity of β-galactosidases (discussed above) while α-GOS can be found 
in natural reservoirs such as soybeans[89]. α-GOS (galactosyl-sucrose oligosaccharides) 
include raffinose, stachyose and verbascose and consist of galactose residues linked α (1–6) 
to the glucose moiety of sucrose (Table 1). Given that most mammals do not express 
pancreatic α –Galactosidases (α (1–6) Gal), its digestion is mediated by colonic bacterial 
enzymes. The fermentation of α (1–6) GOS results in fermentative gases, which can induce 
abdominal pain and flatulence[114, 144]. Bacterial α (1–6) Galactosidases (EC 3.2.1.22) are 
clustered into families 4, 27 and 36 of the sequence-based classification of glycoside 
hydrolases (GH)[48, 49]. A search for EC 3.2.1.22 in the Kyoto Encyclopedia of Genes and 
Genomes (KEGG)[63] retrieved 1,114 hits, including genes from Bifidobacterium and 
Lactobacillus, indicating that α–Gal hydrolases are widely distributed in microbial 
communities. α–Gal enzymes have been identified and characterized in several 
microorganisms including L. plantarum[143], L. reuteri[153], Thermotoga neapolitana[32], 
Bacillus stearothermophilus[149], Enterococcus faecium[168], Enterobacter cloacae[107], 
Citrobacter freundii[141], species of Bifidobacterium[53, 169] and recently, Ruminococcus 
gnavus, a human intestinal isolate[2]. The R. gnavus α–Gal is encoded by the aga1 gene, 
which is 2.2 kb in size, monocistronic, and predicted to encode a 743-amino acid (aa) 
protein, with a 41% similarity to the α–Gal encoded by Thermotoga[2]. In L. plantarum 
ATCC 8014, α–Gal is encoded by the melA gene. The enzyme has a predicted 738 aa-size 
and a molecular mass of 84 kDa. Although melA is flanked by two terminators, it is 
immersed in a gene cluster involved in utilization of α- and β-galactosidases, including rafP, 
a putative raffinose transporter. No sorting signals were identified in the protein encoded by 
melA suggesting its presence as a soluble enzyme in the cytoplasm of L. plantarum[143]. 
According to the KEGG database, α–Gal hydrolyzes terminal, non-reducing α-D-galactose 
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residues in α-D-galactosides, including GOS, galactomannans, galactolipids, and also 
hydrolyzes α-D-fucosides[145]. A protein search at NCBI (http://www.ncbi.nlm.nih.gov/
guide/proteins/) performed in June of 2014, showed 22,588 bacterial entries for α–Gal 
enzymes, with 6,632 representatives in the Firmicutes phylum (almost 50% of those 
corresponding to the order Lactobacillales), 7,430 entries in the Proteobacteria (mostly 
gamma-Proteobacteria), and 4,797 entries in the phylum Actinobacteria (mostly 
Actinomycetales).
1.3. GOS effects on host physiology and immune system
Numerous research studies have shown that prebiotics have an effect on the intestinal 
microbiota (discussed above). The anaerobic breakdown of GOS and other prebiotics 
increase the concentration of fermentation products like lactate and SCFAs, which per se 
affect the intestinal physiology. The purpose of this section is to summarize available 
information concerning a direct effect of GOS on the intestinal cells and physiology.
A potential effect of GOS on the intestinal mucus layer has been described in a number 
studies; however, the molecular mechanisms involved have not been fully elucidated. In the 
colon, the mucus layer is a bilayered system. The outer layer, which can be removed by 
suction, appears to be vital in reducing shear stress to the mucosa[4], and can also trap 
bacterial pathogens. The underlying adherent layer, which cannot be removed by suction, is 
normally free of bacteria and may act as a size exclusion barrier to prevent translocation of 
damaging luminal agents [19, 47]. Brownlee et al.[19] showed that rats consuming a diet 
containing cellulose or a fiber-deficient diet had significantly lower colonic resting mucus 
thickness. Conversely, rats fed ispaghula (a plant of the genus Plantago commonly used as 
used as a bulk-forming laxative) had a significantly thicker adherent layer and higher total 
mucus secretion. The authors hypothesized that there could be a direct molecular interaction 
between specific dietary fibers and the colonic mucin. Moreover, complex carbohydrates 
from fiber could be absorbed through colonic antigen-presenting cells resulting in 
stimulation of mucus production. A study by Zhong et al. (2009) showed that GOS feeding 
significantly improved intestinal barrier function in rats with severe acute pancreatitis[170]. 
An earlier study by Meslin et al.[88] showed that consumption of β (1–4) GOS [(referred as 
trans galacto-oligosaccharides (TOS) in the study] modified the mucin cell distribution in 
the colon of germ-free rats. The authors hypothesized that the lower number of mucus cells 
observed for the three types of mucins (neutral, acid, and sulphonated) in the proximal colon 
and the greater number in the distal colon was related to changes in osmolality produced by 
β (1–4) GOS. Conversely, β (1–4) GOS had no effect in the colon of conventional animals, 
but reduced the number of acid mucin containing cells in the cecum, maybe due to higher 
concentrations of SCFA in the cecum[88]. Interestingly, a study on the small intestine of 
BALB/c mice showed that protein content of the mucosa of β (1–4) GOS-consuming mice 
was higher than controls, and β (1–4) GOS ingestion also increased significantly the mucin 
content compared to controls. However, expression of MUC-2 and MUC-4 encoding the 
major mucins found in the colon, showed no significant differences between β (1–4) GOS -
consuming mice and controls[70], contrarily to a reported increased MUC-3 expression 
induced by inulin feeding in three-week old Sprague–Dawley rats[111]. Taken together, these 
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findings suggest that β (1–4) GOS might estimulate mucus production; however, the 
mechanisms involved in such estimulation are not well understood.
The gastrointestinal tract hosts a major part of the body’s immune system: the gut-associated 
lymphoid tissue. Few reports have studied interactions between GOS and the mucosal 
immune system of the gut, and, given their effect on the intestinal microbiota, it is not easy 
to elucidate whether prebiotics exert direct or indirect modulatory effects. A recent study 
investigated the efficacy of β (1–4) GOS on colitis development in Smad3−/− mice after 
infection with Helicobacter hepaticus[45]. The study found that β (1–4) GOS reduced the 
severity of colitis, augmented NK cell function and IL-15 production. This was associated 
with 1.5-fold increase in fecal bifidobacteria. In a different study, Vaisman et al.[154] 
investigated the effect of a mixture of FOS, β (1–4) GOS, and acidic oligosaccharides on the 
number and consistency of stools and on immune system biomarkers in children age 9 to 24 
months with acute diarrhea. No significant effects were observed on stool characteristics 
over the first 10 days of treatment, or cytokine profiles during the first 2–3 days of 
treatment. In fact, a large variability in magnitude and direction of cytokine secretion was 
detected in patients included in the study. However, when the authors further divided each 
group dichotomously according to the percentage of subjects who had an increase, no 
change or a decrease in the levels of different cytokines over the first 2–3 days of treatment, 
they observed that levels of TNF-α decreased significantly more in the prebiotics 
supplemented group. Finally, a study investigated the effects of β (1–4) GOS as potential 
modulators of the elderly intestinal microbiota and their immune system[161]. In the double-
blind, placebo-controlled, crossover study, the authors detected significant increases in 
phagocytosis, NK cell activity, and IL-10 production and a significant reduction of 
proinflammatory cytokines (IL-6, IL-1β, and tumor necrosis factor-α). It is clear from the 
limited number of research studies that more studies in animal models as well as in humans 
are needed to demonstrate an influence of GOS on the immune system. Especially 
considering that a number of studies suggest a beneficial effect of FOS[9, 37, 54, 167] and 
HMOs (reviewed by Vos et al.[160]).
In addition to the impact on the gut microbiome and the host immune system, prebiotics 
may exert beneficial effects by directly inhibiting the adherence of pathogens to the host 
epithelial cell surface. The proposed mechanism of action is based on the observation that 
the structure of free oligosaccharides and glycoproteins of human breast milk can resemble 
pathogen receptors on intestinal epithelial cells and may act as anti-adhesive molecules that 
competitively inhibit bacterial adherence[68]. In vitro studies showed that GOS significantly 
inhibited adhesion of microcolony-forming enteropathogenic Escherichia coli E2348/69 on 
HEp-2 and Caco-2 cells in a dose dependent fashion[142] and reduced the invasion and 
adherence of Salmonella Thyphimurium in three dimensionally cultured HT-29-16E 
cells[136]. Moreover, a research study showed that GOS low molecular weight fractions 
(primarily tri and tetra-saccharides) in BiMuno® significantly stimulated both pro- and anti-
inflammatory cytokines in vitro, a mechanism that may contribute to a reduction in 
Salmonella Typhimurium colonization ability[137]. Additionally, dietary GOS 
supplementation in neonates in combination with B. breve and B. vulgatus may be an 
important factor for suppressing growth of C. perfringens[93].
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1.4. Enzymatic synthesis of β (1–4) GOS
For a long time, lactose was considered an inconvenient sub product of the dairy industry 
and a health issue in dairy products due to lactose intolerance in a growing number of 
individuals. Therefore, lactose hydrolysis to glucose and galactose using β-galactosidases 
was a common practice until the beneficial impact of GOS on GI health was acknowledged 
and methods to recycle lactose into a functional food ingredient [β (1–4) GOS] were 
envisioned. Prior to that GOS generation during this enzymatic process was usually 
observed and considered detrimental albeit low accumulation of GOS normally occurs 
during commercial fermented food preparations[81]. Multiple β-galactosidases have been 
evaluated to improve GOS synthetic activity; however, since they are predominantly 
hydrolytic enzymes, their efficiency to generate pure GOS is generally limited. Several 
reactor designs and operational processes have been designed to improve GOS synthesis 
efficiency[58, 152], but lactose conversion into β (1–4) GOS never exceeds 50%. Such is the 
case for the β-galactosidase catalyzing the generation of Vivinal GOS® or the process using 
Sporobolomyces singularis membrane bound β-hexosyl transferase to catalyze the synthesis 
of Oligomate 55N/55NP (Figure 1). In the final formulation of these products there are 
significant concentrations of lactose, glucose, and galactose (sugars that can impact the 
physiological influence of the prebiotic) and the final β (1–4) GOS composition and purity 
vary due to fundamental process differences. Therefore, the traditional options are β-
galactosidases (glycosyl-hydrolases or galactosydases) versus β-hexosyl transferases 
(glycosyl-transferases or glucosydases). The soluble β-hexosyl transferase from 
Sporobolomyces singularis permits a more controllable process able to reach values of 95% 
β (1–4) GOS with a narrower spectrum of oligosaccharides (mostly β (1–4) GOS-3 and β (1–
4) GOS-4) and only a residual small proportion of lactose[28].
1.5. Conclusion
Prebiotics have been consumed by humans for millennia. Moreover, the general health 
benefits associated with prebiotic consumption have been clearly recognized in the past 
century. Nonetheless, it is now, with the advent of next generation sequencing technology 
and bioinformatics tools that researchers have the opportunity to dissect dietary effects and 
identify key bacterial players, components of the gut microbiota, influencing fermentation 
and generation of secondary metabolites. This review presented research studies on GOS 
and CRC that clearly suggest a potential role in prevention. Moreover, this role is supported 
by a randomized, double-blind, diet-controlled clinical trial that demonstrated that GOS 
significantly increased fecal acetate and decreased DCA and beta-glucuronidase activity in 
healthy adult men[158]. A clear association between GOS and CRC progression however 
remains to be elucidated.
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• β (1–4) galacto-oligosaccharides [β (1–4) GOS], lactulose and fructo-
oligosaccharides are prebiotics that have clear role in colorectal cancer (CRC) 
prevention.
• β (1–4) GOS increase intestinal concentration of lactate and short chain fatty 
acids as well as stool frequency and weight, and they decrease fecal 
concentration of the secondary bile acid lithocholic acid, fecal pH, and 
nitroreductase and β-glucuronidase activities.
• This review summarizes the current state of research on the bioassimilation of 
prebiotics through modulation of the intestinal microbiota, and the impact of 
prebiotics on host physiology and immune system.
• We also present studies on a potential role in CRC progression and briefly 
describe the current state of β (1–4) GOS enzymatic synthesis for industrial 
production.
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Purity comparison of residual sugars (lactose, galactose and glucose) and β (1–4) GOS 
(Gos-3, Gos-4, Gos-5) present in GOS NCSU, Oligomate 55NP (Yakult), Vivinal GOS 
(Friesland Campina Dome). The enzymes used to generate these products were β-hexosyl-
transferase (GOS NCSU and Oligomate 55NP) and β-galactosidase (Vivinal GOS).
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Summary of the potential impact of β (1–4) GOS on CRC prevention and progression 
according to published scientific literature.
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